News

This vaccine is designed for preventing infections caused by the bacterial pathogen Staphylococcus aureus (S. aureus). S. aureus, a Gram-positive bacterium, affects about 30% of people, causing a

ATX101 is designed for sustained, localised pain relief post total knee arthroplasty surgery. Under the agreement, Allay will receive an upfront payment and equity investment. It is also

ZORYVE foam offers quick disease clearance and major reduction in itch, with nearly 80% of individuals meeting the primary efficacy endpoint of IGA Success and just more than

This drug is intended for adult patients with RCC after a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine

As per the terms of the agreement, Aldevron will get global manufacturing and commercialisation rights to Codex HiCap RNA Polymerase, and in exchange Codexis will get payments for

The alliance brings together and leverages etherna’s mRNA capabilities and LNP formulations with Almirall’s expertise in medical dermatology to speed up the discovery of new treatment options. The

The company entered into the asset purchase agreement in accordance with Regulation 596/2014/EU. Lavipharm is expected to commercialise the product on completing the relevant marketing authorisation transfer, set

AML is a fast-developing cancer originating in the blood and bone marrow, impacting myeloid cells that typically transform into different types of mature blood cells. REZLIDHIA is a

With this acceptance, NextPoint Therapeutics now intends to begin a first-in-human Phase I clinical trial in early 2024 analysing NPX887 in patients with solid tumours known to express